Copyright
©The Author(s) 2020.
World J Clin Cases. Apr 26, 2020; 8(8): 1424-1443
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424
Table 9 Administered antibodies in the first-line setting according to RAS mutation status and progression-free survival time
| RAS status | Bevacizumab, n (%) | PFS | Panitumumab, n (%) | PFS | Total, n (%) | PFS | |
| LCC | RAS wild type | 20 (17.6) | 12.3 | 27 (23.7) | 15.8 | 47 (41.3) | 14.0 |
| RAS mutant | 35 (30.7) | 11.6 | - | - | 35 (30.7) | 11.6 | |
| Total | 55 (48.3) | 11.6 | 27 (23.7) | 15.8 | 82 (72.0) | 12.2 | |
| RCC | RAS wild type | 4 (3.4) | 22.2 | 8 (7.0) | 5.5 | 12 (10.4) | 13.8 |
| RAS mutant | 20 (17.6) | 10 | - | - | 20 (17.6) | 10 | |
| Total | 24 (21.0) | 12.6 | 8 (7.0) | 5.5 | 32 (28.0) | 12.5 | |
| Total | 79 (69.3) | 12 | 35 (30.7) | 14.5 | 114 (100.0) | 12.3 |
- Citation: Kalantzis I, Nonni A, Pavlakis K, Delicha EM, Miltiadou K, Kosmas C, Ziras N, Gkoumas K, Gakiopoulou H. Clinicopathological differences and correlations between right and left colon cancer. World J Clin Cases 2020; 8(8): 1424-1443
- URL: https://www.wjgnet.com/2307-8960/full/v8/i8/1424.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i8.1424